Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Medeical Therapy For Pulmonary Arterial Hypertention

폐동맥고혈압에서 폐혈관계 작용약물

  • Choi, Hye Sook (Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Sang Do (Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 최혜숙 (울산대학교 의과대학 서울아산병원 호흡기내과학교실) ;
  • 이상도 (울산대학교 의과대학 서울아산병원 호흡기내과학교실)
  • Published : 2006.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Pulmonary arterial hypertension (PAH) is often difficult to diagnose and challenging to treat. Untreated, it is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and death. The past decade has seen remarkable improvements in therapy, driven largely by the conduct of randomized controlled trials. Still, the selection of most appropriate therapy is complex, and requires familiarity with the disease process, evidence from treatment trials, complicated drug delivery systems, dosing regimens, side effects, and complications. We tried to provide evidence-based treatment recommendations for physicians involved in the care of these complex patients. Due to the complexity of the diagnostic evaluation required, and the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialized center.

Keywords

References

  1. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. The acute administration of vasodilator s in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989;140:1623-30 https://doi.org/10.1164/ajrccm/140.6.1623
  2. S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81 https://doi.org/10.1056/NEJM199207093270203
  3. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5 https://doi.org/10.1056/NEJM199207093270202
  4. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32 https://doi.org/10.1164/ajrccm.159.6.9804054
  5. RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302 https://doi.org/10.1056/NEJM199602013340504
  6. DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectum of disease: a randomized, controlled trial. Ann Intern Med 2000;132:425-34
  7. G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostimil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a doubleblind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4 https://doi.org/10.1164/ajrccm.165.6.2106079
  8. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986;30:61-8 https://doi.org/10.1007/BF00614197
  9. MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000;35:176-82 https://doi.org/10.1016/S0735-1097(99)00494-5
  10. T, Schmehl T, Hoeper MM, Rose F, Ghofrani HA, Olschewski H, et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J 2001;17:14-9 https://doi.org/10.1183/09031936.01.17100140
  11. H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9 https://doi.org/10.1056/NEJMoa020204
  12. Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365 https://doi.org/10.1016/S0140-6736(97)24019-5
  13. N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki S, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1-188-92 https://doi.org/10.1016/S0735-1097(99)00201-6
  14. Galie N, Humber M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, doubleblind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502 https://doi.org/10.1016/S0735-1097(02)01786-2
  15. RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25 https://doi.org/10.1016/S0735-1097(03)00463-7
  16. MR. Endothelin-1: a mediator of pulmonary hypertension? Pulm Pharmacol Ther 1998;11:125-32 https://doi.org/10.1006/pupt.1998.0126
  17. A, Remuzzi G. Endothelin antagonists. Lancet 1999;353:133-8 https://doi.org/10.1016/S0140-6736(98)09423-9
  18. SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31 https://doi.org/10.1152/jappl.1995.79.6.2122
  19. NS, Warburton RR, Pietras L, Klinge JR. Nonspecific endothelin-receptor antagonist blunts monocrotalinein-duced pulmonary hypertension in rats. J Appl Physiol 1997;83:1209-15 https://doi.org/10.1152/jappl.1997.83.4.1209
  20. JM, Wellmann SA, McNamara JL, Lombardi JP, Wagner CJ, Raake JL, et al. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. Ann Thorac Surg 1999;68:1714-21 https://doi.org/10.1016/S0003-4975(99)00988-1
  21. C, Chan MF, Stavros F, Raju B, Okun I, Mong S, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997;40:1690-7 https://doi.org/10.1021/jm9700068
  22. RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23 https://doi.org/10.1016/S0140-6736(01)06250-X
  23. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7 https://doi.org/10.1164/rccm.200307-957OC
  24. Hanson KA, Burns F, Rybalkin SD, Miller JW, Beavo J, Clarke WR. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 1998;158:279–88
  25. Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, Clarke WR. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 1998;275:L931–41
  26. Braner DA, Fineman JR, Chang R, Soifer SJ. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol 1993; 264:H252–8
  27. McMahon TJ, Ignarro LJ, Kadowitz PJ. Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J Appl Physiol 1993;74:1704–11
  28. Clarke WR, Uezono S, Chambers A, Doepfner P. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm Pharmacol 1994;7:81–9 https://doi.org/10.1006/pulp.1994.1009
  29. Cohen AH, Hanson K, Morris K, Fouty B, McMurty IF, Clarke W, et al. Inhibition of cyclic3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996;97:172–9
  30. Thusu KG, Morin FC 3rd, Russell JA, Steinhorn RH. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect ofnitric oxide. Am J Respir Crit Care Med 1995;152:1605-10 https://doi.org/10.1164/ajrccm.152.5.7582302
  31. Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Clarke WR, Abman SH. Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. Am J Respir Crit Care Med 1998;157:1104–10
  32. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136;515-22 https://doi.org/10.1001/archinte.136.5.515
  33. E, Tymchak W, Lien D, webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-403 https://doi.org/10.1161/01.CIR.0000016641.12984.DC
  34. JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM,et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002;90:677-80 https://doi.org/10.1016/S0002-9149(02)02586-9
  35. AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91:307-10 https://doi.org/10.1097/00000542-199907000-00041
  36. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22 https://doi.org/10.1161/hc3601.096826
  37. SH, Charfield BA, Hall SL, McMurtry IF. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 1990;259:H1921-7.
  38. Villamor E, Le Cras TD, Horan MP, Halbower AC, Tuder RM, Abman SH. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. Am J Physiol 1997;27-2:L1013-20
  39. KA, Fouty BW, Tyler RC, Morris KG Jr, Hepler LK, Sato K, et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest 1999;103:291-9 https://doi.org/10.1172/JCI3862
  40. JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997;48:489-509 https://doi.org/10.1146/annurev.med.48.1.489
  41. RD,Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998;101:731-6 https://doi.org/10.1172/JCI1699
  42. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995;38:87-104 https://doi.org/10.1016/S0033-0620(05)80001-5
  43. Buechler WA, Ivanova K, Wolfram G, Drummer C, Heim TM, Gerzer R. Soluble guanylyl cyclase and platelet function. Am N Y Acad Sci 1994;714:151-7 https://doi.org/10.1111/j.1749-6632.1994.tb12039.x
  44. Radomski MW, Moncada S. The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol 1993;344:251-64
  45. Zapol WM, Falke KJ, Hurford WE, Roberts JD Jr. Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator. Chest 1994;105:87S-91S https://doi.org/10.1378/chest.105.1.87
  46. JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-20 https://doi.org/10.1016/0140-6736(92)92687-B
  47. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997;336:597-604 https://doi.org/10.1056/NEJM199702273360901